Holmium Laser Enucleation of the Prostate in Patients Requiring Anticoagulation

Marcelino Rivera, Amy Krambeck, James Lingeman

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Purpose of Review: This is to evaluate and discuss the literature surrounding holmium laser enucleation of the prostate (HoLEP) in patients on anticoagulation. Recent Findings: The relationship of benign prostatic hyperplasia (BPH) to bothersome lower urinary tract symptoms (LUTS) is well established with a majority of men over the age of 60 having significant symptoms. Patients with severe enough symptoms often require surgery and with cardiovascular disease ranking as the primary cause of death in the USA, a growing number will be taking antiplatelet (AP) or anticoagulation (AC) for primary or secondary prevention of disease. A review of the recent literature focusing on patients on AP/AC undergoing HoLEP noted minimal adverse effects in the postoperative course aside from prolonged bleeding requiring catheterization with continuous bladder irrigation. Summary: Although patients with BPH and bothersome LUTS undergoing HoLEP are at a slightly greater risk for prolonged bladder irrigation secondary to bleeding, surgical outcomes are similar to men not on AP/AC. The literature surrounding newer direct oral anticoagulants (DOACs) and HoLEP is limited, and therefore, conclusions regarding continuation of DOACs cannot be drawn. However, HoLEP appears to be a safe and effective procedure for BPH-related LUTS in patients on AP/AC therapy.

Original languageEnglish (US)
Article number77
JournalCurrent Urology Reports
Volume18
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Solid-State Lasers
Prostate
Lower Urinary Tract Symptoms
Prostatic Hyperplasia
Anticoagulants
Urinary Bladder
Hemorrhage
Primary Prevention
Secondary Prevention
Catheterization
Cause of Death
Cardiovascular Diseases

Keywords

  • Anticoagulation
  • Benign prostatic obstruction
  • Holmium laser enucleation of the prostate (HoLEP)
  • Lower urinary tract symptoms

ASJC Scopus subject areas

  • Urology

Cite this

Holmium Laser Enucleation of the Prostate in Patients Requiring Anticoagulation. / Rivera, Marcelino; Krambeck, Amy; Lingeman, James.

In: Current Urology Reports, Vol. 18, No. 10, 77, 01.10.2017.

Research output: Contribution to journalReview article

@article{be800ba890e84299a8cfcb3f11dc43d8,
title = "Holmium Laser Enucleation of the Prostate in Patients Requiring Anticoagulation",
abstract = "Purpose of Review: This is to evaluate and discuss the literature surrounding holmium laser enucleation of the prostate (HoLEP) in patients on anticoagulation. Recent Findings: The relationship of benign prostatic hyperplasia (BPH) to bothersome lower urinary tract symptoms (LUTS) is well established with a majority of men over the age of 60 having significant symptoms. Patients with severe enough symptoms often require surgery and with cardiovascular disease ranking as the primary cause of death in the USA, a growing number will be taking antiplatelet (AP) or anticoagulation (AC) for primary or secondary prevention of disease. A review of the recent literature focusing on patients on AP/AC undergoing HoLEP noted minimal adverse effects in the postoperative course aside from prolonged bleeding requiring catheterization with continuous bladder irrigation. Summary: Although patients with BPH and bothersome LUTS undergoing HoLEP are at a slightly greater risk for prolonged bladder irrigation secondary to bleeding, surgical outcomes are similar to men not on AP/AC. The literature surrounding newer direct oral anticoagulants (DOACs) and HoLEP is limited, and therefore, conclusions regarding continuation of DOACs cannot be drawn. However, HoLEP appears to be a safe and effective procedure for BPH-related LUTS in patients on AP/AC therapy.",
keywords = "Anticoagulation, Benign prostatic obstruction, Holmium laser enucleation of the prostate (HoLEP), Lower urinary tract symptoms",
author = "Marcelino Rivera and Amy Krambeck and James Lingeman",
year = "2017",
month = "10",
day = "1",
doi = "10.1007/s11934-017-0727-2",
language = "English (US)",
volume = "18",
journal = "Current Urology Reports",
issn = "1527-2737",
publisher = "Current Science, Inc.",
number = "10",

}

TY - JOUR

T1 - Holmium Laser Enucleation of the Prostate in Patients Requiring Anticoagulation

AU - Rivera, Marcelino

AU - Krambeck, Amy

AU - Lingeman, James

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Purpose of Review: This is to evaluate and discuss the literature surrounding holmium laser enucleation of the prostate (HoLEP) in patients on anticoagulation. Recent Findings: The relationship of benign prostatic hyperplasia (BPH) to bothersome lower urinary tract symptoms (LUTS) is well established with a majority of men over the age of 60 having significant symptoms. Patients with severe enough symptoms often require surgery and with cardiovascular disease ranking as the primary cause of death in the USA, a growing number will be taking antiplatelet (AP) or anticoagulation (AC) for primary or secondary prevention of disease. A review of the recent literature focusing on patients on AP/AC undergoing HoLEP noted minimal adverse effects in the postoperative course aside from prolonged bleeding requiring catheterization with continuous bladder irrigation. Summary: Although patients with BPH and bothersome LUTS undergoing HoLEP are at a slightly greater risk for prolonged bladder irrigation secondary to bleeding, surgical outcomes are similar to men not on AP/AC. The literature surrounding newer direct oral anticoagulants (DOACs) and HoLEP is limited, and therefore, conclusions regarding continuation of DOACs cannot be drawn. However, HoLEP appears to be a safe and effective procedure for BPH-related LUTS in patients on AP/AC therapy.

AB - Purpose of Review: This is to evaluate and discuss the literature surrounding holmium laser enucleation of the prostate (HoLEP) in patients on anticoagulation. Recent Findings: The relationship of benign prostatic hyperplasia (BPH) to bothersome lower urinary tract symptoms (LUTS) is well established with a majority of men over the age of 60 having significant symptoms. Patients with severe enough symptoms often require surgery and with cardiovascular disease ranking as the primary cause of death in the USA, a growing number will be taking antiplatelet (AP) or anticoagulation (AC) for primary or secondary prevention of disease. A review of the recent literature focusing on patients on AP/AC undergoing HoLEP noted minimal adverse effects in the postoperative course aside from prolonged bleeding requiring catheterization with continuous bladder irrigation. Summary: Although patients with BPH and bothersome LUTS undergoing HoLEP are at a slightly greater risk for prolonged bladder irrigation secondary to bleeding, surgical outcomes are similar to men not on AP/AC. The literature surrounding newer direct oral anticoagulants (DOACs) and HoLEP is limited, and therefore, conclusions regarding continuation of DOACs cannot be drawn. However, HoLEP appears to be a safe and effective procedure for BPH-related LUTS in patients on AP/AC therapy.

KW - Anticoagulation

KW - Benign prostatic obstruction

KW - Holmium laser enucleation of the prostate (HoLEP)

KW - Lower urinary tract symptoms

UR - http://www.scopus.com/inward/record.url?scp=85026999808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026999808&partnerID=8YFLogxK

U2 - 10.1007/s11934-017-0727-2

DO - 10.1007/s11934-017-0727-2

M3 - Review article

C2 - 28780634

AN - SCOPUS:85026999808

VL - 18

JO - Current Urology Reports

JF - Current Urology Reports

SN - 1527-2737

IS - 10

M1 - 77

ER -